semaglutide heart failure reduced ejection fraction and cardiovascular outcomes in patients with obesity and prevalent failure: a prespecified analysis of the SELECT trial Mechanisms of GLP-1 Receptor Agonists

Seeking out healthcare providers with obesity medicine expertise, rather than general practitioners unfamiliar with these medications, often improves the treatment experience

For many employees, access to these medications can have a significant impact on: Overall health Energy levels Productivity Long-term healthcare outcomes Flexible Plan Design GLP-1 HRAs can often be customized to fit an employers goals and budget

Additionally, while no significance was found, a trend to an increase in food intake with intraperitoneal injection of HU210 was observed

Proactive measures can significantly reduce the risk of temperature-related damage to future semaglutide shipments

PlexusDx's genetic test identifies variants in GLP1R (rs6923761), GIPR (rs1800437), and 47 other peptide-pathway genes